Free Trial
NASDAQ:GCTK

GlucoTrack (GCTK) Stock Price, News & Analysis

GlucoTrack logo
$1.74
+0.06 (+3.57%)
(As of 11/1/2024 ET)

About GlucoTrack Stock (NASDAQ:GCTK)

Key Stats

Today's Range
$1.74
$1.80
50-Day Range
$1.68
$2.92
52-Week Range
$0.66
$4.95
Volume
2,064 shs
Average Volume
24,889 shs
Market Capitalization
$9.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

GlucoTrack Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
6th Percentile Overall Score

GCTK MarketRank™: 

GlucoTrack scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GlucoTrack is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GlucoTrack is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GlucoTrack has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about GlucoTrack's valuation and earnings.
  • Percentage of Shares Shorted

    0.72% of the float of GlucoTrack has been sold short.
  • Short Interest Ratio / Days to Cover

    GlucoTrack has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlucoTrack has recently decreased by 11.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    GlucoTrack does not currently pay a dividend.

  • Dividend Growth

    GlucoTrack does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.72% of the float of GlucoTrack has been sold short.
  • Short Interest Ratio / Days to Cover

    GlucoTrack has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlucoTrack has recently decreased by 11.98%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GlucoTrack insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.30% of the stock of GlucoTrack is held by insiders.

  • Percentage Held by Institutions

    Only 10.92% of the stock of GlucoTrack is held by institutions.

  • Read more about GlucoTrack's insider trading history.
Receive GCTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter.

GCTK Stock News Headlines

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

GCTK Stock Analysis - Frequently Asked Questions

GlucoTrack's stock was trading at $1.3075 at the beginning of 2024. Since then, GCTK stock has increased by 33.1% and is now trading at $1.74.
View the best growth stocks for 2024 here
.

GlucoTrack, Inc. (NASDAQ:GCTK) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.82) earnings per share for the quarter.

Shares of GlucoTrack reverse split on the morning of Monday, May 20th 2024. The 1-5 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Cybin (CYBN), Cyclo Therapeutics (CYTH), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:GCTK
Employees
5
Year Founded
N/A

Profitability

Net Income
$-7,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.77 per share

Miscellaneous

Free Float
5,133,000
Market Cap
$9.54 million
Optionable
Not Optionable
Beta
0.13
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:GCTK) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners